August 1, 2018 | Lao Tribune

Daily Archives August 1, 2018

CORRECTION FROM SOURCE: Transport Canada Certifies 90-Seat Cabin ...

Launch customer SpiceJet of India to become first airline to take advantage of the extra-capacity turboprop’s increased profitability potential TORONTO, Aug. 01, 2018 (GLOBE NEWSWIRE) — This document corrects and replaces the press release that was sent today at 9:00 am EDT. Bombardier Commercial Aircraft announced today that its 90-passenger Q400 aircraft configuration has received […]Read More

Williams Scotsman to Announce Second Quarter 2018 Results on August ...

BALTIMORE, Aug. 01, 2018 (GLOBE NEWSWIRE) — WillScot Corporation (Nasdaq: WSC) (“Williams Scotsman”) today announced that it will release its second quarter 2018 financial results Tuesday, August 7, 2018 after the markets close. President and Chief Executive Officer, Brad Soultz, and Chief Financial Officer, Tim Boswell, will host a conference call and webcast on Wednesday, August 8, 2018 at 10:00 […]Read More

CORRECTING and REPLACING — Neuralstem, Inc.

GERMANTOWN, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) — In a release issued yesterday by Neuralstem, Inc. (Nasdaq:CUR), please note the headline should be, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke,” rather than, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke,” as originally issued. The corrected […]Read More

Luxury Brand House of Sillage Launches Limited-Edition Lipstick Case ...

Also Wins Award for Product Innovation, Luxury Item at the ICMAD City Awards NEWPORT BEACH, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) — House of Sillage a leader in luxury haute parfumerie, is excited to announce its expansion into cosmetics with its limited-edition lipstick case and refill. Available exclusively at select Neiman Marcus stores and online […]Read More

Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 ...

GERMANTOWN, Md., July 31, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced the initiation of a Phase 2 clinical trial evaluating NSI-566, the Company’s lead neural stem cell candidate, as a potential treatment for ischemic stroke. […]Read More